Akebia Therapeutics Files 8-K Report
Ticker: AKBA · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing, exhibits
Related Tickers: AKBA
TL;DR
AKBA filed an 8-K today, mostly financial docs. Nothing major flagged yet.
AI Summary
On October 22, 2024, Akebia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status and operations. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing serves as a public record of Akebia Therapeutics' financial disclosures, providing transparency to investors and stakeholders regarding the company's financial health and operational status.
Risk Assessment
Risk Level: low — The filing appears to be a standard 8-K for financial statements and exhibits, not indicating any immediate or significant risks.
Key Numbers
- 001-36352 — SEC File Number (Akebia's SEC registration identifier)
- 20-8756903 — IRS Employer Identification No. (Akebia's tax identification number)
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- 0001517022-24-000070 (document_id) — Accession Number
- 20241022 (date) — Filing Date
- 245 First Street Cambridge, Massachusetts 02142 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Akebia Therapeutics?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was this 8-K report filed with the SEC?
This 8-K report was filed on October 22, 2024.
What is Akebia Therapeutics, Inc.'s principal executive office address?
Akebia Therapeutics, Inc.'s principal executive office is located at 245 First Street, Cambridge, Massachusetts 02142.
What is the SIC code for Akebia Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Akebia Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing indicate any specific material event or transaction?
Based on the provided excerpt, the filing is primarily for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', and does not detail any specific material events or transactions.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-22 08:05:56
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke
Filing Documents
- akba-20241022.htm (8-K) — 31KB
- akebiadocontract_finalx102.htm (EX-99) — 35KB
- 0001517022-24-000070.txt ( ) — 209KB
- akba-20241022.xsd (EX-101.SCH) — 2KB
- akba-20241022_def.xml (EX-101.DEF) — 4KB
- akba-20241022_lab.xml (EX-101.LAB) — 24KB
- akba-20241022_pre.xml (EX-101.PRE) — 14KB
- akba-20241022_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 22, 2024, Akebia Therapeutics, Inc. (the "Company") issued a press release announcing that it signed a multi-year commercial supply agreement with a leading dialysis organization to enable access to Vafseo (vadadustat) for patients on dialysis. A copy of the Company's press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K ("Report") and is incorporated herein by reference. The information in this Report (including Item 7.01 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 22 , 202 4 , issued by Akebia Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date: October 22, 2024 By: /s/ John P. Butler Name: John P. Butler Title: President and Chief Executive Officer